OncoMatch

OncoMatch/Clinical Trials/NCT03125577

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

Is NCT03125577 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for b-cell malignancies.

Phase 1/2RecruitingShenzhen Geno-Immune Medical InstituteNCT03125577Data as of Jun 2026Location: China

Treatment: 4SCAR19 and 4SCAR22 · 4SCAR19 and 4SCAR38 · 4SCAR19 and 4SCAR20 · 4SCAR19 and 4SCAR123 · 4SCAR19 and 4SCAR70 · 4SCAR19 and 4SCAR30The study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) and CD20 (4SCAR20), CD22 (4SCAR22), CD30 (4SCAR30), CD38 (4SCAR38), CD70 (4SCAR70) or CD123 (4SCAR123) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

4SCAR19 and 4SCAR224SCAR19 and 4SCAR384SCAR19 and 4SCAR204SCAR19 and 4SCAR1234SCAR19 and 4SCAR704SCAR19 and 4SCAR30

Biomarker criteria

Required: CD123 surface expression

Required: CD19 surface expression

Required: CD20 surface expression

Required: CD22 surface expression

Required: CD30 surface expression

Required: CD38 surface expression

Required: CD70 surface expression

Demographics

Ages 0–75

Prior therapy

Cannot have received: car-t cell therapy

Lab requirements

Blood counts

hgb > 80 g/l

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT03125577 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior car-t cell therapy disqualifies patients from enrollment.

Does this trial require CD123?

Yes, CD123 surface expression is a required biomarker for enrollment.

Does this trial require CD19?

Yes, CD19 surface expression is a required biomarker for enrollment.

Does this trial require CD20?

Yes, CD20 surface expression is a required biomarker for enrollment.

Is there an age limit?

Yes. Patients must be 75 years or younger and at least 0 years old.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify